Trial Profile
A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) Versus Bupivacaine Alone in Subjects Undergoing Elective Cesarean Section
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2021
Price :
$35
*
At a glance
- Drugs Bupivacaine (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors Pacira BioSciences
- 12 Jul 2020 Results assessing adding LB to TAP block with BUPI HCl would reduce opioid consumption through 72 hours compared with BUPI HCl alone.published in the Anesthesia and Analgesia
- 07 May 2019 Results presented in the Pacira BioSciences media release.
- 07 May 2019 According to a Pacira Pharmaceuticals media release, full results from the trial were presented at the 51st Annual Meeting of the Society of Obstetric Anesthesia and Perinatology (SOAP) in Phoenix.